Summary:
An epidemiological investigation from Durham University reveals that the mental health benefits linked to classic psychedelics, such as psilocybin and LSD, vary significantly across human lifespans. Published in Scientific Reports, the study analyzed survey data from 1,088 adults aged 18 to 55 and older, evaluating lifetime psychedelic use alongside validated anxiety, depression, and well-being scales.
Researchers discovered that adults in their twenties and early thirties with a history of classic psychedelic use reported significantly lower levels of depression and anxiety compared to non-users. However, this mental health association diminished progressively with age and disappeared entirely in older cohorts, a divergence largely explained by the higher intensity of mystical-type experiences reported by younger individuals.
Key Facts:
- Age-Dependent Association: Classic psychedelic use (psilocybin, LSD) was strongly associated with lower anxiety and depression scores in younger adults (twenties and early thirties), but the relationship weakened across midlife and vanished completely among older participants.
- The Mystical Experience Factor: Statistical modeling demonstrated that younger users reported more intense “mystical-type” experiences during psychedelic sessions, which mediated the association between substance history and reduced psychological distress.
- Substance-Specific Comparison: The study included an active comparison cohort of non-classic psychoactive users (those who used MDMA or ketamine but never classic psychedelics), confirming that the age-related mental health associations were unique to classic 5-HT2A agonists rather than general drug-seeking traits.
Source: Durham University / Scientific Reports
As psychedelic-assisted psychotherapy moves through advanced clinical trials for major depressive disorder, generalized anxiety, and treatment-resistant post-traumatic stress, neuroscientists are working to understand the demographic, psychological, and neurobiological parameters that dictate therapeutic efficacy.
While clinical trials focus on short-term symptom reduction under structured medical supervision, evaluating the long-term mental health footprints of naturalistic psychedelic use across diverse populations remains essential for establishing realistic clinical expectations.
In an investigation published in Scientific Reports (a Nature Portfolio journal), researchers at Durham University in the United Kingdom evaluated the relationship between lifetime psychedelic use and contemporary mental health across the adult lifespan.
Their findings demonstrate that age plays a governing role: while young adults who have used classic psychedelics show marked reductions in anxiety and depression, this protective association fades systematically with advancing age.
Surveying Over 1,000 Lifespans
Led by doctoral researcher Giammarco Di Gregorio under the supervision of neurobiologist Dr. Marco Bocchio and psychologist Dr. Michael Lengieza at Durham University’s Department of Psychology, the team analyzed responses from 1,088 adults aged 18 to over 55.
Participants provided comprehensive histories of their lifetime psychoactive substance use and completed validated psychometric batteries measuring depression, anxiety, subjective well-being, and life satisfaction.
To isolate true substance-specific outcomes from general sensation-seeking behaviors, the researchers partitioned respondents into four distinct analytical cohorts:
- Classic Psychedelic Users: Individuals who used 5-HT2A receptor agonists, including psilocybin (“magic mushrooms”), LSD, DMT, or mescaline.
- Non-Classic Psychoactive Users: Individuals who had taken psychoactive substances like ketamine or MDMA, but had never ingested classic psychedelics.
- Dual Users: Individuals with histories involving both classic and non-classic compounds.
- Substance-Naïve Controls: Individuals who had never consumed either class of substance.
This inclusion of non-classic users served as a rigorous methodological control, allowing the team to test whether psychological differences were driven by classic psychedelics specifically or merely by general personality traits common among people drawn to altered states of consciousness.
The Youth Advantage and the Mystical Connection
Cross-sectional analysis revealed a clear demographic divergence. Among adults in their twenties and early thirties, a history of classic psychedelic use was robustly tied to lower baseline anxiety and depression scores relative to non-user peers.
However, as participant age increased, this positive association steadily attenuated. In cohorts aged 40 and older—and particularly those 55 and above—the mental health difference between classic psychedelic users and non-users flattened entirely.
The association held true even after controlling for potential confounding factors, including lifetime frequency of use, elapsed time since last exposure, and typical dosage.
The researchers traced the root of this age divergence to the phenomenological quality of the psychedelic state itself.
“Age remains a relatively underexplored factor in psychedelic research,” said lead author Giammarco Di Gregorio. “There’s growing evidence that younger people tend to have more intense, mystical-type experiences while on psychedelics. Our study suggests this may matter for mental health. The link between classic psychedelic use and lower anxiety and depression was strongest in younger adults and faded with age, and the mystical experiences younger users reported helped to explain that pattern.”
Implications for Stratified Clinical Trials
Because psychedelic clinical trials typically enroll tightly filtered, relatively narrow demographic bands, large-scale naturalistic studies provide essential clues for clinical trial design.
“One of the strengths of this study is that it allowed us to examine psychedelic use and mental health associations in a large sample with a broad age range, which can be difficult to achieve in clinical trials,” said co-supervisor Dr. Marco Bocchio. “By analysing data from more than 1,000 participants, we were able to identify age-related patterns that might otherwise be missed.”
Bocchio highlighted the importance of their pharmacological control group: “A novelty of our study was the inclusion of a comparison group of people who had used ‘non classic psychedelics’, such as ketamine or MDMA, but not classic psychedelics. This helped us test whether the patterns we observed were specific to classic psychedelics, rather than reflecting broader differences between people who are drawn to psychoactive substances and altered states of consciousness.”
Study Caveats and Translational Horizons
The investigators emphasize that the cross-sectional, self-reported design of the study demonstrates an epidemiological association, not direct biological causation. It remains plausible that younger individuals with greater baseline psychological resilience or specific neuroplastic profiles are both more likely to navigate intense mystical experiences and less vulnerable to mood disorders.
To clarify the causal mechanisms, the Durham team is preparing longitudinal protocols that track cognitive metrics, personality shifts, and mental health trajectories before and after psychedelic administration across different decades of life.
As regulatory agencies evaluate psychedelic therapies, factoring in biological aging, receptor density changes, and subjective experience intensity will be vital for determining which patients stand to benefit most from these emergent treatments.
Questions and Answers
What was the main finding of the Durham University psychedelic study?
The study found that adults in their twenties and early thirties who had used classic psychedelics (like psilocybin and LSD) reported lower levels of anxiety and depression than non-users. However, this positive mental health link weakened with age and was completely absent in older adults.
Why does the relationship between psychedelics and mental health fade with age?
The researchers found that younger adults report significantly more intense “mystical-type” experiences during their trips. These subjective mystical experiences mediated the link to lower anxiety and depression, suggesting that younger brains may be more receptive to the transformative psychological effects of psychedelics.
Does this study prove that taking psilocybin or LSD cures depression in young adults?
No. The study is observational and cross-sectional, relying on self-reported retrospective surveys. While it identifies an intriguing age-stratified association, it cannot prove direct cause and effect, nor does it suggest individuals should self-medicate outside of clinical settings.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this neuroscience Research:
- Media Contact: Alexa Fox
- Source: Durham University
- Image Credit: Image credited to Neuroscience News
- Original Research is Open Access: Scientific Reports (Nov 9, 2026). “Age moderates the relationship between psychedelic use and mental health in naturalistic settings.” Authors: Giammarco Di Gregorio, Sophia Basset, Harjot Manmohan, Warren C. Nixon, Amrutha Pogaku, Jing Zhou, David J. Sanderson, Michael L. Lengieza & Marco Bocchio.
- DOI: 10.1038/s41598-026-68283-2
Abstract
Age moderates the relationship between psychedelic use and mental health in naturalistic settings
Depression and anxiety affect one in five adults and vary across the lifespan; while prevalence generally declines with age until midlife, later life is marked by a re-emergence of symptoms. Although clinical trials suggest classic psychedelics (e.g., psilocybin, LSD) and non-classic psychedelics (e.g., MDMA, ketamine) may alleviate these symptoms, it remains unclear how these relationships function in naturalistic settings or how they vary across the lifespan.
We conducted a cross-sectional survey of 1,088 adults (18–55 + years) to assess how lifetime psychedelic use – categorised as classic, non-classic, or mixed – relates to mental health. We found that age significantly moderates the relationship between lifetime history of psychedelic use and mental health measures. Specifically, classic psychedelic use was linked to lower depression and anxiety among younger adults, but these effects diminished with age.
These associations persisted independently of drug-use parameters, including dosage, frequency, and recency of use. Moderated-mediation analyses indicated that mystical-type experiences accounted for the associations with both depression and anxiety among younger adults, but not among older adults, where a residual association with anxiety remained independent of mystical experience.
These findings suggest that age may be a meaningful moderator of mental health outcomes from psychedelic use. This underscores the potential value of age-stratified research to optimise the efficacy and safety of psychedelic-assisted interventions.
